Key Drivers
- Strong liquidity
- Zero revenue
- Persistent losses
AIAI Summary
SION has shifted from a financing-risk story to a binary near-term clinical catalyst trade, with a strong cash runway through 2028 reducing dilution risk but leaving the stock highly dependent on summer 2026 data to justify its premium valuation; investors should focus on whether SION-719 and SION-451 deliver differentiated results, because a miss could trigger a sharp re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •Persistent losses
SION has a very strong balance sheet with ample cash and minimal debt, but zero revenue, persistent operating losses, negative cash flow, and a rich 6.4x P/B valuation make it a high-risk, balance-sheet-dependent story.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •High-$30s support
- •Low-$40s cap
SION's short-term trend is mixed to slightly negative: despite repeated rebounds from the high-$30s, the failed breakout after the 2026-05-11 peak and continued weakness into 2026-05-15 leave the stock capped in the low-$40s until it reclaims that area.
Sharp reversal after the 2026-05-11 peak with follow-through weakness into 2026-05-15
Sentiment & News
Key News Insights:
- •Insider Selling
- •Trial Progress
- •Cash Runway
Sionna drew attention from a cluster of director insider sales, but completed Phase 2a enrollment, on-track clinical data timelines, and a ~$289.9M cash position through 2028 keep the outlook constructive.
The insider sales may create near-term pressure, but the strong balance sheet and advancing pipeline milestones support a positive medium-term view on the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings